Références bibliographiques

1. *Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.*

2. *Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2010;144:646-74.*

3. *Weinstein B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002;297:63-4.*

4. *Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.*

5. *Inoue A, Suzuki T, Fukuhara T et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-6.*

6. *Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.*

7. *Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57.*

8. *Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362(25):2380-8.*

9. *Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.*

10. *Zhou C, Wu YL, Chen G et al. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations. ESMO 2010, abstract LBA13.*

11. *Rosell R, Gervais R, Vergnenegre A et al. Erlotinib versus chemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. ASCO 2011, abstract 7503.*

12. *Zhou W, Ercan D, Chen L et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462(7276):1070-4.*

13. *Miller VA, Hirsh V, Cadranel J et al. Phase IIB/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-LUNG 1). ESMO 2010, abstract 4089.*

14. *Janjigian YY, Groen HJ, Horn L et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. ASCO 2011, abstract 7525.*

15. *Spigel DR, Ervin TJ, Ramlau R et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. ASCO 2011, abstract 7505.*

16. *Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703.*

17. *Shaw AT, Yeap BY, Solomon BJ et al. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. ASCO 2011, abstract 7507.*

18. *Choi YL, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363(18):1734-9.*

19. *Mitsudomi T, Tomizawa K, Horio Y et al. Comparison of high sensitive IHC, FISH and RT-PCR direct sequencing for detection of ALK translocation in lung cancer. ASCO 2011, abstract 7534.*

20. *Camidge DR, Kono SA, Flacco A et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010;16:5581-90.*

21. *Greillier L. Cibler aussi le mésothéliome pleural malin et le cancer bronchique à petites cellules. Rev Mal Respir Actual 2011;3:416-22.*

22. *Greillier L, Marco S, Barlesi F. Targeted therapies in malignant pleural mesothelioma: a review of clinical studies. Anticancer Drugs 2011;22:199-205.*

23. *Krug LM, Kindler HL, Calvert H et al. VANTAGE 014: Vorinostat in patients with advanced malignant pleural mesothelioma (MPM) previously treated with pemetrexed and either cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial. ESMO 2011, abstract 3BA.*

24. *Langer CJ, Albert I, Kovacs P et al. A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC). ASCO 2011, abstract 7001.*

25. *Pujol JL, Breton JL, Gervais R et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 2007;25:3945-51.*

26. *Lee SM, Woll PJ, Rudd R et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009;101:1049-57.*

27. *Baas P, Buikhuisen W, Dalesio O et al. A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy. ASCO 2011, abstract 7006.*

28. *Zalcman G, Margery J, Scherpereel A et al. IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. ASCO 2010, abstract 7020.*

29. *Spigel DR, Townley PM, Waterhouse DM et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011;29:2215-22.*

Agenda

Cours intensifs de TDM multicoupe du thorax

Lille, du 2 au 4 février 2012, du 13 au 15 septembre 2012 et du 13 au 15 décembre 2012.

Organisation : Pr M. Rémy-Jardin, Pr J. Rémy, Dr J.B. Faivre.
Ce cours intensif de TDM thoracique est destiné à un public de médecins en cours de formation ou de spécialistes confirmés.

Renseignements : secrétariat du service de radiologie, hôpital Calmette, boulevard du Pr-Jules-Leclercq – 59037 Lille Cedex.
Tél. : 03 20 44 43 11. Fax : 03 20 44 47 20.
E-mail : martine.remy@chru-lille.fr